User account menu Search Menu Investors Creating value for our company, our shareholders and society We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value. R&D Day 2021 December 02, 2021 – Virtual 14:00-19:00 CET | 13:00-18:00 GMT | 08:00-13:00 EST Investors Event Calendar View recent presentations and learn more about upcoming events. Learn More Environmental, Social and Governance (ESG) Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen. Learn More ESG Updates: Oct 27, 2021 (PDF 0.5 MB) | July 22, 2021 (PDF 1.8 MB) | Apr 28, 2021 (PDF 0.3 MB) | Jan 27, 2021 (PDF 0.5 MB) Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessments Webinars We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics. Explore the ESG Indices Novartis ESG Investor Day 2021 Novartis shared progress on its most material ESG topics. Watch highlights Read the press release Download slide deck (PDF 9.6 MB) Stocks Media Releases November 4, 2021 Media Release New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio November 4, 2021 Media Release Novartis to sell its Roche stake in a bilateral transaction to Roche November 4, 2021 Media Release Novartis verkauft ihre Roche-Beteiligung in einer bilateralen Transaktion an Roche All Media Releases Pulse Updates September 28, 2021 FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC) Read More September 03, 2021 Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients Read More September 02, 2021 Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee Read More Aug 30, 2021 Novartis sabatolimab receives orphan drug designation from the European Commission for myelodysplastic syndromes Read More View all Pulse Updates Novartis COVID-19 Information Center Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources. Enter the Information Center Investor Relations Contacts For questions about investor relations or the share registry, please contact our team. Learn More Stay Up-to-Date Stay connected to the latest news and information from Novartis Novartis AG Lichtstrasse 35 CH-4056 Basel, Switzerland Novartis Navigate Topics Explore Companies Footer Bottom © 2021 Novartis AG Terms of Use Privacy Contacts Cookie Settings Site Map Novartis Site Directory This site is intended for a global audience Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies, select “Cookie settings” for managing the different cookies or select “Reject all” for using only strictly necessary cookies. You can change your cookie settings at any point of time by pressing the cookie settings link on the website. Cookie Settings Reject all Accept all